PMC9254302_01
Position in a pan-cancer dimension reduction plot generated with the http://www.epidip.org tool.
pha-0107-0433-g01.jpg
PMC9254302_01_pha-0107-0433-g01.jpg
F1
DNA methylome did not match to any of the defined glioblastoma, IDH wildtype, subgroups, and lacked the prototypical +7/-10 chromosomal signature of glioblastoma, IDH wildtype; highest classifier v11b4 calibrated scores for glioblastoma, IDH wildtype (0.38, no match; cut-off >=0.9), subclass RTK I (0.25). Dimension reduction showed some similarity to glioblastoma, IDH wildtype but did not fall into any of the distinct clusters (Fig. 1).
Schematic representation of the NTRK3-ARHGEF7 fusion.
pha-0107-0433-g02.jpg
PMC9254302_01_pha-0107-0433-g02.jpg
F2
Targeted RNA sequencing identified an NTRK3 (exon 15) - ARHGEF7 (exon 17) fusion (Fig. 2).
T1-weighted (upper panel) and T2-weighted MRI of the brain (gadolinium administration) before and after larotrectinib treatment.
pha-0107-0433-g03.jpg
PMC9254302_01_pha-0107-0433-g03.jpg
F3
Six weeks after treatment initiation, a brain MRI revealed partial response according to RANO criteria (Fig. 3).
Timeline of interventions and treatments.
pha-0107-0433-g04.jpg
PMC9254302_01_pha-0107-0433-g04.jpg
F4
Sustained clinical benefit was preserved 2 months after stop of larotrectinib and 6 months after diagnosis (Fig. 4).